Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish.
Duchenne muscular dystophy (DMD) is a severe muscle wasting disease caused by mutations in the dystrophin gene. By utilizing antisense oligonucleotides, splicing of the dystrophin transcript can be altered so that exons harbouring a mutation are excluded from the mature mRNA. Although this approach has been shown to be effective to restore partially functional dystrophin protein, the level of dystrophin protein that is necessary to rescue a severe muscle pathology has not been addressed. As zebrafish dystrophin mutants (dmd) resemble the severe muscle pathology of human patients, we have utilized this model to evaluate exon skipping. Novel dmd mutations were identified to enable the design of phenotype rescue studies via morpholino administration. Correlation of induced exon-skipping efficiency and the level of phenotype rescue suggest that relatively robust levels of exon skipping are required to achieve significant therapeutic ameliorations and that pre-screening analysis of exon-skipping drugs in zebrafish may help to more accurately predict clinical trials for therapies of DMD.
Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.
Joachim
J
Berger
Silke
S
Berger
Arie S
AS
Jacoby
Steve D
SD
Wilton
Peter D
PD
Currie
D000818:Animals; D030801:Animals, Genetically Modified; D016189:Dystrophin / Q000502:physiology*; D005091:Exons / Q000235:genetics*; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics*; D010641:Phenotype; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D015027:Zebrafish / Q000235:genetics* / Q000254:growth & development / Q000378:metabolism
D016189:Dystrophin; D012333:RNA, Messenger
Proc Natl Acad Sci U S A. 1984 Feb;81(4):1189-92
6583703
Hum Mol Genet. 1998 May;7(5):919-32
9536098
Nat Rev Genet. 2007 May;8(5):353-67
17440532
Hum Mol Genet. 2009 Jan 1;18(1):202-11
18957474
J Med Genet. 1993 Sep;30(9):728-36
8411067
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):42-7
11120883
Mol Ther. 2009 Aug;17(8):1418-26
19293776
FEBS Lett. 1994 May 16;344(2-3):255-60
8187894
Curr Med Chem. 2007;14(22):2413-20
17896989
Lancet Neurol. 2009 Oct;8(10):918-28
19713152
Development. 1996 Dec;123:399-413
9007258
N Engl J Med. 2007 Dec 27;357(26):2677-86
18160687
Am J Hum Genet. 1992 May;50(5):950-9
1570844
Gene Ther. 2006 Oct;13(19):1373-81
16724091
Neuromuscul Disord. 2010 Jan;20(1):64-70
19944604
Hum Mol Genet. 2001 Jul 15;10(15):1547-54
11468272
Neuromuscul Disord. 1994 Jul;4(4):349-58
7981592
Hum Mutat. 2009 Mar;30(3):293-9
19156838
Neuromuscul Disord. 2010 Dec;20(12):826-32
20850317
Neurology. 1989 Aug;39(8):1011-7
2668783
Development. 2003 Dec;130(23):5851-60
14573513
Ann Neurol. 2009 Jun;65(6):667-76
19288467
Nat Med. 2002 Mar;8(3):253-61
11875496